Lite Strategy, Inc. Increase Decrease In Operating Lease Liability
Lite Strategy, Inc. (LITS) reported Increase Decrease In Operating Lease Liability of $0 for the 12-month period ending 2025-06-30, per its 10-K filed 2025-09-26.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2025-09-26
- Lite Strategy, Inc. increase decrease in operating lease liability for the quarter ending 2025-06-30 was $0.00.
- Lite Strategy, Inc. increase decrease in operating lease liability for the quarter ending 2025-03-31 was $0.00.
- Lite Strategy, Inc. increase decrease in operating lease liability for the quarter ending 2024-12-31 was $0.00.
- Lite Strategy, Inc. increase decrease in operating lease liability for the quarter ending 2024-09-30 was $0.00.
- Lite Strategy, Inc. increase decrease in operating lease liability for fiscal 2025 was $0.00.
- Lite Strategy, Inc. increase decrease in operating lease liability for fiscal 2024 was -$13.61M.
- Lite Strategy, Inc. increase decrease in operating lease liability for fiscal 2023 was -$1.26M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-26 | $0.00 derived: sum of 2 quarters · filed 2025-09-26 | $0.00 derived: sum of 3 quarters · filed 2025-09-26 | $0.00 10-K · filed 2025-09-26 |
| 2025-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-13 | $0.00 derived: sum of 2 quarters · filed 2025-05-13 | $0.00 10-Q · filed 2025-05-13 | -$12.55M derived: sum of 4 quarters · filed 2025-09-26 |
| 2024-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-12 | $0.00 10-Q · filed 2025-02-12 | -$12.55M derived: sum of 3 quarters · filed 2025-09-26 | -$12.91M derived: sum of 4 quarters · filed 2025-09-26 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-12 | -$12.55M derived: sum of 2 quarters · filed 2025-09-26 | -$12.91M derived: sum of 3 quarters · filed 2025-09-26 | -$13.27M derived: sum of 4 quarters · filed 2025-09-26 |
| 2024-06-30 | -$12.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-26 | -$12.91M derived: sum of 2 quarters · filed 2025-09-26 | -$13.27M derived: sum of 3 quarters · filed 2025-09-26 | -$13.61M 10-K · filed 2025-09-26 |
| 2024-03-31 | -$360.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-13 | -$714.00K derived: sum of 2 quarters · filed 2025-05-13 | -$1.06M 10-Q · filed 2025-05-13 | -$1.39M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$354.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-12 | -$701.00K 10-Q · filed 2025-02-12 | -$1.02M derived: sum of 3 quarters · filed 2025-02-12 | -$1.34M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-09-30 | -$347.00K 10-Q · filed 2024-11-12 | -$671.00K derived: sum of 2 quarters · filed 2024-11-12 | -$989.00K derived: sum of 3 quarters · filed 2024-11-12 | -$1.30M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$324.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-19 | -$642.00K derived: sum of 2 quarters · filed 2024-09-19 | -$954.00K derived: sum of 3 quarters · filed 2024-09-19 | -$1.26M 10-K · filed 2024-09-19 |
| 2023-03-31 | -$318.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-09 | -$630.00K derived: sum of 2 quarters · filed 2024-05-09 | -$937.00K 10-Q · filed 2024-05-09 | |
| 2022-12-31 | -$312.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-13 | -$619.00K 10-Q · filed 2024-02-13 | ||
| 2022-09-30 | -$307.00K 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |